Two individuals with neuromyelitis optica spectrum disorder (NMOSD) have been in remission for over 15 years following a single stem-cell transplant, according to Nature. This outcome marks the first reported use of allogeneic haematopoietic stem-cell transplant to treat NMOSD. Such long-term disease control for a rare, debilitating autoimmune condition challenges traditional lifelong management.
However, stem cell therapies, while proving remarkably effective at inducing long-term remission for severe autoimmune diseases, often require intensive and risky pre-treatment regimens. Patients must weigh this remarkable efficacy against potentially life-threatening preparations.
Based on the evidence of sustained remission and significant disease control, stem cell therapies are poised to become a more widely adopted, albeit intensive, treatment option for specific autoimmune conditions, shifting the approach from symptom management to potential cure.
